Valeant To Drop Deal-Making To Cut Debt, Boost Stock

December 10, 2014
By Mark Terry, BioSpace.com Breaking News Staff

Quebec-based Valeant Pharmaceuticals International is apparently going to drop its growth-by-acquisitions strategy, according to insiders. Known as a “serial acquirer,” the Canadian drugmaker has acquired more than 100 smaller companies since 2008.

Valeant has been embroiled in a takeover bid of Allergan Inc. (AGN) with New York hedge fund Pershing Square Capital Management since August. Repeatedly rebuffed by the Botox maker, the bid has also inspired a Security and Exchange Commission (SEC) investigation into allegations of insider trading.

In March of this year, Pershing Square bought up 10% of Allergan’s stock. A month later Valeant and Pershing Square announced their joint bid for the company, which resulted in a 15% stock increase, which resulted in $1 billion in gains for Pershing Square.

In November Allergan agreed to be bought for $66 billion by Actavis. In 2013 Actavis, which had been headquartered in Parsippany, N.J., acquired Irish company Warner Chilcott and changed its domicile to Ireland in a tax inversion deal.

Northern’s management said its main priorities over the next two years will be the recruitment of its scientific team and successfully shepherding its first drug candidates into human clinical trials. The company is already in active recruitment and expects to have a team of at least 20 people in place by the end of 2015.

"The more people we can have working on targeted therapies, the more quickly we will be able to have a significant impact on patient outcomes," noted Christopher Paige, vice president of research at UHN. "Patients expect us to be working in partnership, and Northern Biologics is a prime example of collaborative success."

Northern said Wednesday that it will now focus its funding on growing its oncology and and fibrosis therapies as it attempts to take on much larger companies in a crowded and competitive antibodies market.

“Antibodies and other medical products from biological sources play an expanding, revolutionary role as alternatives to small molecule drugs by treating disease in a more targeted way and reducing side effects," said Peter Lewis, interim vice president of research and Innovation at U of T. "Northern Biologics is a prime example of the way in which cross-collaboration works to advance and ultimately commercialize the innovative science that is happening in Canadian laboratories."

Teaming of with Versant appears to be a strategic move designed to help Northern move closer to eventually going public. Since its creation in 1999, nearly 40 Versant companies have achieved successful acquisitions or IPOs, and Versant has $1.9 billion under management and offices in North America and Europe.

“We continue to be impressed by the innovative healthcare investment opportunities we see in Canada," said Versant Partner Jerel Davis. "Versant believes in investing in early stage companies with robust discovery platforms and portfolios, and our investment in Northern Biologics will fund the advancement of several assets in parallel."

Larson agreed with Davis and said he looked forward to guiding the company forward.

"Northern Biologics is a great example of the kind of exciting and innovative early-stage company we can build when world-class science comes together with entrepreneurial and seasoned venture capital investors," said Larson, who notes that close collaboration between venture capital and academic institutions is still rare in Canada. "We are now in a position to rapidly advance several potential new antibody therapies toward the clinic."